non-Hodgkin lymphoma Archives

Janssen has signed a licence and option deal with Denmark’s Genmab to develop a next-generation drug that it

Janssen to develop Darzalex successor with Genmab

https://pharmaphorum.com/news/janssen-to-develop-darzalex-successor-with-genmab/

The FDA has quickly approved a new antibody treatment for an aggressive form of lymphoma from Roche –

FDA approves Roche’s $90,000 lymphoma combination

https://pharmaphorum.com/news/fda-approves-roches-90000-lymphoma-combination/

Germany’s Morphosys has announced results from its combination therapy of an experimental antibody and Celgene’s Revlimid in a

Morphosys to take on CAR-Ts in NHL with promising antibody

https://pharmaphorum.com/news/morphosys-to-take-on-car-ts-in-nhl-with-promising-antibody/

It has been a busy month already in the field of CAR-T therapy, with Gilead expanding a partnership

Gilead expands CAR-T deal with MaxCyte, Precision files for $100m IPO

https://pharmaphorum.com/news/gilead-expands-car-t-deal-with-maxcyte-precision-files-for-100m-ipo/

NICE has recommended regular NHS funding for Takeda’s Adcetris in an aggressive type of non-Hodgkin lymphoma after the

Adcetris cleared by NICE in aggressive blood cancer

https://pharmaphorum.com/news/takedas-adcetris-cleared-nhs-funding-aggressive-blood-cancer/

But rival Juno finally gives up on lead therapy.

Kite and Fosun appoint leader for CAR-T debut in China

https://pharmaphorum.com/news/kite-pushes-t-cell-joint-venture-china/

Imbruvica approved in marginal zone lymphoma.

J&J/AbbVie blood cancer drug gets fifth US indication

https://pharmaphorum.com/news/jjabbvie-blood-cancer-drug-gets-fifth-us-indication/

Biotech plans pivotal trial next year.

Juno boosted by CAR-T trial findings in NHL

https://pharmaphorum.com/news/juno-boosted-car-t-trial-findings-nhl/

non-Hodgkin lymphoma